Savara (NASDAQ:SVRA) Receives Buy Rating from HC Wainwright

Savara (NASDAQ:SVRA)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 135.85% from the company’s previous close.

A number of other brokerages have also weighed in on SVRA. JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Savara in a report on Monday, September 9th. Oppenheimer raised their price objective on Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 26th. Finally, Guggenheim upped their target price on Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $11.17.

Savara Stock Performance

Shares of SVRA stock opened at $4.24 on Tuesday. Savara has a 12-month low of $3.12 and a 12-month high of $5.70. The business’s fifty day simple moving average is $4.33 and its 200-day simple moving average is $4.46. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. The company has a market cap of $585.92 million, a PE ratio of -11.46 and a beta of 0.97.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Analysts expect that Savara will post -0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Several hedge funds have recently modified their holdings of the company. Frazier Life Sciences Management L.P. boosted its position in Savara by 103.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. Nantahala Capital Management LLC raised its position in Savara by 198.2% during the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after acquiring an additional 3,443,541 shares during the period. Farallon Capital Management LLC lifted its holdings in Savara by 90.5% during the second quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock valued at $18,377,000 after purchasing an additional 2,165,701 shares in the last quarter. Wellington Management Group LLP acquired a new stake in shares of Savara in the fourth quarter valued at about $9,683,000. Finally, First Light Asset Management LLC purchased a new stake in shares of Savara during the second quarter worth about $8,069,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.